Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4).May 29, 2024 | ASCO, Comunicaciones a congresos, Pilar Canoa Román, Sergio Vazquez-Estevez
Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.Ene 22, 2024 | Alberto Carral Maseda, ASCO, Borja Gonzalez Gómez, Comunicaciones a congresos
